RITXUMIAB RADIATION UNFOLDER TRIAL SERIES
RITXUMIAB RADIATION UNFOLDER TRIAL FREE

Staging was based on the Ann Arbor classification.

The diagnosis of DLBCL was confirmed by hematopathologists at XXXX University according to World Health Organization classification. Imaging response assessment was based on consensus recommendations from the International Harmonization Project in Lymphoma. Patients who received radiation therapy, did not achieve CR, or had involvement of the central nervous system were excluded from our analysis. These adverse risk factors would then enable radiation oncologists in better identifying future stage III/IV patients who would likely benefit the most with the addition of consolidative radiotherapy.ДЄfter obtaining XXXX Institutional Review Board approval, we reviewed the records of 211 histologically confirmed stage III-IV DLBCL patients treated with rituximab in addition to CHOP or CHOP-like chemotherapy at XXXX University between 8/1999 and 1/2012. We attempted to clarify this by the identification of adverse risk factors predicting for increased local recurrence (LR) in patients who received a complete response (CR) with rituximab-based chemotherapy. Given the preceding results, we sought to identify a subgroup of patients with advanced stage DLBCL who could benefit from consolidative RT in the modern treatment era. While there may be a benefit to the addition of RT in some patients, advanced stage DLBCL represents a heterogeneous disease. Additionally, a recently published prospective nonrandomized trial, including stage III and IV patients, demonstrated improvements in both PFS and OS for в‰Ґ70 year old patients with в‰Ґ7.5 cm bulky disease with the addition of consolidative RT following R-CHOP.

RITXUMIAB RADIATION UNFOLDER TRIAL SERIES

Retrospective series have shown improvement in both PFS and OS with the addition of RT following complete response to chemotherapy. However, there is evidence that consolidative RT can improve outcomes in advanced stage disease. The role of RT is especially unclear in the setting of advanced stage disease in which systemic relapse is thought to drive outcomes and improved local control with the addition of radiotherapy may be less of an issue. With the dramatic improvement in outcomes in the rituximab era, the question is raised whether radiation therapy is still needed. Other studies conclude that there is no benefit from radiation in this setting, but these were all conducted in the pre-rituximab era. Randomized evidence has shown that RT improves the rate of recurrence and possibly survival in stage I and II DLBCL. Radiation therapy (RT) is often recommended in the consolidative setting following complete response after chemotherapy, particularly for stage I and II DLBCL patients.

RITXUMIAB RADIATION UNFOLDER TRIAL FREE

Prolonged disease free survival rates are poor following relapse. Relapse after initial treatment typically requires high-dose therapy with autologous stem cell transplant. However, outcomes remain poor in stage III and IV disease with progression free survival (PFS) and overall survival (OS) at ten years of 37% and 44%, respectively. The addition of rituximab to standard chemotherapy has improved outcomes in this disease. About two thirds of these patients present with advanced disease. Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease that represents the most common subtype of non-Hodgkin lymphoma in the United States.

Ritxumiab radiation unfolder trial